a Institute of Dermatology , Catholic University - Fondazione Policlinico Universitario A. Gemelli IRCCS , Rome , Italy.
b Section of Dermatology and Venereology, Department of Medicine , University of Verona , Verona , Italy.
Expert Opin Pharmacother. 2019 May;20(7):863-872. doi: 10.1080/14656566.2019.1583207. Epub 2019 Feb 22.
Psoriasis is a chronic inflammatory skin disease that is increasingly being recognized as a complex disorder affecting multiple systems. Systemic inflammation is considered the pathogenic link between psoriasis and its comorbid conditions that include arthritis, metabolic disorders, depression, and cardiovascular diseases. The presence of comorbid conditions modifies both its clinical management and the therapeutic approach in psoriatic patients.
This review describes the clinical, epidemiological, and pathogenic link between psoriasis and obesity. Furthermore, data related to the effects of synthetic antipsoriatic drugs on obesity are collated.
Obesity is one of the most common comorbid conditions that is relevant both for a patient's overall health and the clinical outcomes of antipsoriatic therapies. Indeed, some treatments of psoriasis might be impaired by adiposity. Moreover, obesity's association with dyslipidemia, hypertension, and increased liver enzymes could further be worsened by acitretin, cyclosporine and methotrexate, respectively. Therefore, the identification of therapeutic targets whose blockade could have positive effects on both psoriasis and mechanisms regulating body weight homeostasis may be of great relevance to the treatment of patients with psoriasis.
银屑病是一种慢性炎症性皮肤病，越来越多的人认识到它是一种影响多个系统的复杂疾病。全身性炎症被认为是银屑病与其合并症之间的致病联系，这些合并症包括关节炎、代谢紊乱、抑郁和心血管疾病。合并症的存在改变了银屑病患者的临床管理和治疗方法。
本文描述了银屑病与肥胖之间的临床、流行病学和发病机制联系。此外，还收集了与合成抗银屑病药物对肥胖影响相关的数据。
肥胖是最常见的合并症之一，它与患者的整体健康和抗银屑病治疗的临床结果都有关。事实上，一些银屑病的治疗可能会因肥胖而受到影响。此外，肥胖与血脂异常、高血压和肝酶升高有关，而阿维 A、环孢素和甲氨蝶呤分别会使这些情况进一步恶化。因此，确定治疗靶点，阻断这些靶点可能对银屑病和调节体重平衡的机制都有积极影响，这可能对银屑病患者的治疗具有重要意义。
